NASDAQ:APRE Aprea Therapeutics Q2 2025 Earnings Report $1.69 -0.02 (-1.17%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.72 +0.03 (+1.72%) As of 08/14/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Aprea Therapeutics EPS ResultsActual EPS-$0.53Consensus EPS -$0.77Beat/MissBeat by +$0.24One Year Ago EPSN/AAprea Therapeutics Revenue ResultsActual Revenue$0.12 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAprea Therapeutics Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateTuesday, August 12, 2025Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aprea Therapeutics Earnings HeadlinesAprea Therapeutics Reports Promising Q2 2025 ResultsAugust 13 at 6:37 AM | msn.comAprea Therapeutics Reports Q2 2025 Financial ResultsAugust 12 at 5:42 PM | msn.comThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.” | Weiss Ratings (Ad)Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical UpdateAugust 12 at 8:00 AM | globenewswire.comAprea Therapeutics (APRE) to Release Quarterly Earnings on MondayAugust 9, 2025 | americanbankingnews.comAprea Therapeutics Inc (APRE) - Investing.comJune 29, 2025 | investing.comSee More Aprea Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email. Email Address About Aprea TherapeuticsAprea Therapeutics (NASDAQ:APRE), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.View Aprea Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Brinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings Beat Upcoming Earnings Palo Alto Networks (8/18/2025)Medtronic (8/19/2025)Home Depot (8/19/2025)Analog Devices (8/20/2025)Synopsys (8/20/2025)TJX Companies (8/20/2025)Lowe's Companies (8/20/2025)Workday (8/21/2025)Intuit (8/21/2025)Walmart (8/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access